One study loaded an ICD inducer, human neutrophil elastase (ELANE), and a TLR3 agonist Hiltonol onto breast cancer-derived Tu-sEVs to form an in situ vaccine (HELA-sEVs) [382]. This evidence concerns the gene TLR3 and breast carcinoma.